9.88
前日終値:
$10.85
開ける:
$10.75
24時間の取引高:
2.22M
Relative Volume:
0.93
時価総額:
$1.21B
収益:
$631.73M
当期純損益:
$-239.78M
株価収益率:
-4.8911
EPS:
-2.02
ネットキャッシュフロー:
$-33.45M
1週間 パフォーマンス:
-13.86%
1か月 パフォーマンス:
-17.25%
6か月 パフォーマンス:
-55.83%
1年 パフォーマンス:
-74.35%
10 X Genomics Inc Stock (TXG) Company Profile
名前
10 X Genomics Inc
セクター
電話
(925) 401-7300
住所
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
TXG を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
TXG
10 X Genomics Inc
|
9.88 | 1.21B | 631.73M | -239.78M | -33.45M | -2.02 |
![]()
VEEV
Veeva Systems Inc
|
227.80 | 36.98B | 2.75B | 714.14M | 1.09B | 4.33 |
![]()
SOLV
Solventum Corp
|
72.30 | 12.51B | 8.26B | 66.00M | 1.17B | 0.3682 |
![]()
DOCS
Doximity Inc
|
60.80 | 11.41B | 516.85M | 174.11M | 217.38M | 0.87 |
![]()
HQY
Healthequity Inc
|
93.97 | 8.14B | 1.15B | 96.70M | -161.99M | 1.09 |
![]()
TEM
Tempus Ai Inc
|
42.16 | 7.26B | 640.44M | -743.28M | -206.93M | -11.29 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-13 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2024-09-03 | 開始されました | Leerink Partners | Outperform |
2024-07-22 | アップグレード | Jefferies | Hold → Buy |
2024-07-18 | ダウングレード | JP Morgan | Overweight → Neutral |
2024-07-10 | ダウングレード | Deutsche Bank | Buy → Hold |
2024-06-27 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
2024-06-25 | ダウングレード | Guggenheim | Buy → Neutral |
2024-06-03 | 再開されました | Jefferies | Hold |
2024-05-01 | ダウングレード | TD Cowen | Buy → Hold |
2023-12-14 | 開始されました | Guggenheim | Buy |
2023-12-13 | 開始されました | Wolfe Research | Outperform |
2023-12-12 | アップグレード | BofA Securities | Underperform → Neutral |
2023-07-05 | 再開されました | JP Morgan | Overweight |
2023-05-10 | 開始されました | Barclays | Overweight |
2023-03-31 | 開始されました | Stephens | Overweight |
2023-02-02 | 開始されました | UBS | Neutral |
2022-12-14 | 開始されました | Deutsche Bank | Buy |
2022-08-18 | ダウングレード | Goldman | Neutral → Sell |
2022-07-25 | 開始されました | Canaccord Genuity | Buy |
2022-07-15 | ダウングレード | BofA Securities | Neutral → Underperform |
2022-07-15 | ダウングレード | William Blair | Outperform → Mkt Perform |
2021-10-15 | 再開されました | Cowen | Outperform |
2021-09-14 | ダウングレード | BofA Securities | Buy → Neutral |
2021-03-15 | 開始されました | William Blair | Outperform |
2020-12-02 | 開始されました | Goldman | Neutral |
2020-09-09 | 開始されました | Morgan Stanley | Overweight |
2020-07-10 | 開始されました | Stifel | Buy |
2020-03-05 | 開始されました | Guggenheim | Buy |
2020-01-07 | 開始されました | Citigroup | Buy |
2019-10-07 | 開始されました | BofA/Merrill | Buy |
2019-10-07 | 開始されました | Cowen | Outperform |
2019-10-07 | 開始されました | JP Morgan | Overweight |
2019-09-24 | 開始されました | Evercore ISI | Outperform |
すべてを表示
10 X Genomics Inc (TXG) 最新ニュース
Long Read Sequencing Market Top Companies Study10X Genomics, - openPR
Bruker motion backfires in US patent dispute with 10x Genomics, Harvard - MLex
10x Genomics IncOrdinary SharesClass A to Host Earnings Call - ACCESS Newswire
10x Genomics’ (TXG) Sell (E+) Rating Reiterated at Weiss Ratings - Defense World
Citigroup Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock Price - Defense World
10x Genomics gets injunction against Parse Biosciences' ATAC Products - MSN
10x Genomics Dodges Appeal In DNA Analysis Patent Clash - Law 360 UK
10x genomics CEO Serge Saxonov sells $84,393 in stock By Investing.com - Investing.com Australia
Rhumbline Advisers Sells 1,641 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
10x genomics CEO Serge Saxonov sells $84,393 in stock - Investing.com
Sanctuary Advisors LLC Purchases 6,474 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
Short Interest in 10x Genomics, Inc. (NASDAQ:TXG) Expands By 34.4% - Defense World
10x Genomics Secures Injunction Against Parse Biosciences' Plann - GuruFocus.com
10x Genomics Secures Injunction Against Parse Biosciences’ Planned ATAC Products - The Malaysian Reserve
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products - Marketscreener.com
10x Genomics secures injunction against Parse Biosciences - Investing.com
10x Genomics gets injunction against Parse Biosciences' ATAC Products (TXG:NASDAQ) - Seeking Alpha
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products – Company Announcement - Financial Times
Patent Victory: How 10x Genomics Just Eliminated a Key Competitor in Genomic Analysis - StockTitan
10 Promising Biotech Stocks to Invest in (March 2025) - Securities.io
ARK Investment Management LLC Purchases 1,193,712 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
SVB Wealth LLC Acquires Shares of 522,609 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Ieq Capital LLC Purchases 50,722 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
ING Groep NV Acquires New Shares in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics, Inc. (NASDAQ:TXG) CEO Sells $56,368.44 in Stock - MarketBeat
Director of 10x Genomics Picks Up 184% More Stock - Simply Wall St
Oxford Nanopore Expands Compatibility With 10x Genomics To Unlock Deeper Insights in Single-Cell Transcriptomics - Technology Networks
10x genomics’ president sells $50,602 in stock - Investing.com India
Insider Buying: 10x Genomics, Inc. (NASDAQ:TXG) Director Buys 40,000 Shares of Stock - MarketBeat
10x genomics CEO Serge Saxonov sells $56,346 in stock - Investing.com India
10x genomics CEO Serge Saxonov sells $56,346 in stock By Investing.com - Investing.com South Africa
10x genomics' president sells $50,602 in stock - Investing.com
10x genomics director Alan Mateo acquires $445,572 in stock - Investing.com
10x Genomics Director Mateo Alan Acquires 40,000 Shares - TradingView
Alberta Investment Management Corp Takes $3.21 Million Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, - GuruFocus.com
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis - Nasdaq
Can 10x Genomics' New 8-Million Cell Platform Transform Genomic Research? - StockTitan
Harvard, 10x Genomics Settle Patent Dispute With Vizgen - Harvard Crimson
10x Genomics, Inc. (NASDAQ:TXG) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
Weiss Ratings Reiterates Sell (E+) Rating for 10x Genomics (NASDAQ:TXG) - Defense World
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference - The Eastern Progress Online
10x Genomics, Inc. (NASDAQ:TXG) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Q1 EPS Estimates for 10x Genomics Lowered by Leerink Partnrs - MarketBeat
10x Genomics (NASDAQ:TXG) Lowered to "Hold" Rating by Leerink Partnrs - MarketBeat
10x Genomics (NASDAQ:TXG) Stock Price Up 8.3%Here's What Happened - MarketBeat
Citigroup Has Lowered Expectations for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat
10x Genomics (NASDAQ:TXG) Price Target Cut to $12.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
10x Genomics' SWOT analysis: genomics firm faces NIH funding headwinds - Investing.com
10x Genomics (NASDAQ:TXG) Shares Gap Down on Disappointing Earnings - MarketBeat
Canaccord Genuity Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $18.00 - MarketBeat
10 X Genomics Inc (TXG) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):